Intellia concludes Phase III ATTRv-PN study enrolment
Intellia Therapeutics has concluded patient enrolment in MAGNITUDE-2, a Phase III clinical study investigating nexiguran ziclumeran, known as nex-z, in adults with hereditary ATTRv-PN.
The post Intellia concludes Phase III ATTRv-PN study enrolment appeared first on Clinical Trials Arena .